Equity Research

Tobacco: SFATA Conference -- Key Takeaways

- E-Cigarette/Nicotine Debate Needs to be Re-Focused on Opportunity to Reduce Net Population-Level Harm Caused by Smoking - We attended the Smoke-Free Alternatives Trade Association (SFATA) Conference outside of Chicago, "headlined" by Mitch Zeller, Director of the FDA's Center for Tobacco Products. Encouragingly, Director Zeller underscored the importance of "opening up the dialogue" across various stakeholders in the nicotine space, suggesting to us that he and the agency remain committed to using science and data to shape regulation while recognizing the nicotine continuum of risk which is consistent with his previous comments. Director Zeller even remarked that conference participants were "preaching to the choir" with regards to the need for the debate to change. Other takeaways from Director Zeller: (1) The societal debate around e-cigs needs to be re-focused on "issues that really matter" - namely what role e-cigs or other potentially less harmful, noncombustible nicotine delivery systems could play in net population-level harm reduction, potentially reversing the trend of 500K Americans dying annually from tobacco-related harm; (2) The issues driving the e-cig/nicotine debate center around youth access, flavors, and marketing, which are undoubtedly very important but have diverted attention from the bigger-picture issues as described in #1; (3) The FDA has "taken seriously" the comments, considerations and concerns of small manufacturers who don't have the financial and human resources of Big Tobacco; and (4) The FDA is engaged with other FDA "centers" – particularly the Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) to explore the role of "therapeutic nicotine." Bottom line - we remain cautiously optimistic that the FDA "gets it" with regards to a nicotine risk continuum that will ultimately be reflected in regulation. We remain bullish on vapor long-term, but near-term we're more cautious given increased uncertainty.
- Rare, Sizeable Opportunity to Reduce Smoking Harm and Generate Profits – Ups the Ante for Industry to "Get it Right" – A consistent theme throughout the day was the need for alternatives for smokers who can't or won't quit, within a "continuum of risk" framework. To achieve this, there were calls to put the "tobacco wars and mentality that goes with it" behind us, take "emotion and rhetoric" out of public debate, and <u>accept the vaping industry must be</u> regulated within a relative risk framework. Further, encouraging examples were cited from public health domains/industries that have embraced harm reduction such as methadone clinics for drug abusers or the auto industry developing safer vehicles. Bottom line – the vapor industry needs to "rise up" and "take the spotlight" away from the anti-e-cig camp which is taking the spotlight right now, promulgating negative public perception.
- Deeming Regulations Industry Encouraged to Think About Regulatory World and Stay Active/Engaged with Regulators – Once the deeming rule is final, it will go to the OMB (Office of Management and Budget) for review (it'll be publically known that the rule is at OMB but not what it says). The OMB's cost/benefit analysis typically will likely take 3-6 months. Regardless of what the final rule entails, conference speakers encouraged the industry to start preparing (compiling ingredients lists, implementing manufacturing standards, etc.), even though implementation and enforcement of the regs will likely take years in our view. Further, the final rule could be more of a "guideline" in nature with guidance being issued over time to govern the specifics as one speaker suggested the FDA has historically regulated by "guidance" which triggers certain specific requirements as the industry evolves.

Please see page 2 for rating definitions, important disclosures and required analyst certifications All estimates/forecasts are as of 05/05/15 unless otherwise stated.

Wells Fargo Securities, LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of the report and investors should consider this report as only a single factor in making their investment decision.

(212) 214-5051

Bonnie Herzog, Senior Analyst

bonnie.herzog@wellsfargo.com Jessica Gerberi, CFA, Associate Analyst (212) 214-5029 jessica.gerberi@wellsfargo.com Adam Scott, Associate Analyst (212) 214-8064 adam.scott@wellsfargo.com

Tobacco

SECURITIES

WELLS

FARGC

Together we'll go far



Required Disclosures

Additional Information Available Upon Request

I certify that:

1) All views expressed in this research report accurately reflect my personal views about any and all of the subject securities or issuers discussed; and

2) No part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this research report.

Wells Fargo Securities, LLC does not compensate its research analysts based on specific investment banking transactions. Wells Fargo Securities, LLC's research analysts receive compensation that is based upon and impacted by the overall profitability and revenue of the firm, which includes, but is not limited to investment banking revenue.

STOCK RATING

1=Outperform: The stock appears attractively valued, and we believe the stock's total return will exceed that of the market over the next 12 months. BUY

2=Market Perform: The stock appears appropriately valued, and we believe the stock's total return will be in line with the market over the next 12 months. HOLD

3=Underperform: The stock appears overvalued, and we believe the stock's total return will be below the market over the next 12 months. SELL

SECTOR RATING

O=Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months. **M=Market Weight**: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months. **U=Underweight**: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

VOLATILITY RATING

V = A stock is defined as volatile if the stock price has fluctuated by +/-20% or greater in at least 8 of the past 24 months or if the analyst expects significant volatility. All IPO stocks are automatically rated volatile within the first 24 months of trading.

As of: May 5, 2015

43% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Outperform.	Wells Fargo Securities, LLC has provided investment banking services for 43% of its Equity Research Outperform-rated companies.
55% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Market Perform.	Wells Fargo Securities, LLC has provided investment banking services for 30% of its Equity Research Market Perform-rated companies.
2% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Underperform.	Wells Fargo Securities, LLC has provided investment banking services for 29% of its Equity Research Underperform-rated

companies.

Important Disclosure for International Clients

EEA – The securities and related financial instruments described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. For recipients in the EEA, this report is distributed by Wells Fargo Securities International Limited ("WFSIL"). WFSIL is a U.K. incorporated investment firm authorized and regulated by the Financial Conduct Authority. For the purposes of Section 21 of the UK Financial Services and Markets Act 2000 ("the Act"), the content of this report has been approved by WFSIL a regulated person under the Act. WFSIL does not deal with retail clients as defined in the Markets in Financial Instruments Directive 2007. The FCA rules made under the Financial Services and Markets Act 2000 for the protection of retail clients will therefore not apply, nor will the Financial Services Compensation Scheme be available. This report is not intended for, and should not be relied upon by, retail clients.

Australia – Wells Fargo Securities, LLC is exempt from the requirements to hold an Australian financial services license in respect of the financial services it provides to wholesale clients in Australia. Wells Fargo Securities, LLC is regulated under U.S. laws which differ from Australian laws. Any offer or documentation provided to Australian recipients by Wells Fargo Securities, LLC in the course of providing the financial services will be prepared in accordance with the laws of the United States and not Australian laws.

Canada – This report is distributed in Canada by Wells Fargo Securities Canada, Ltd., a registered investment dealer in Canada and member of the Investment Industry Regulatory Organization of Canada (IIROC) and Canadian Investor Protection Fund (CIPF).

Hong Kong – This report is issued and distributed in Hong Kong by Wells Fargo Securities Asia Limited ("WFSAL"), a Hong Kong incorporated investment firm licensed and regulated by the Securities and Futures Commission of Hong Kong ("the SFC") to carry on types 1, 4, 6 and 9 regulated activities (as defined in the Securities and Futures Ordinance (Cap. 571 of The Laws of Hong Kong), "the SFO"). This report is not intended for, and should not be relied on by, any person other than professional investors (as defined in the SFO). Any securities and related financial instruments described herein are not intended for sale, nor will be sold, to any person other than professional investors (as defined in the SFO). The author or authors of this report is or are not licensed by the SFC. Professional investors who receive this report should direct any queries regarding its contents to Mark Jones at WFSAL (email: wfsalresearch@wellsfargo.com).

Japan – This report is distributed in Japan by Wells Fargo Securities (Japan) Co., Ltd, registered with the Kanto Local Finance Bureau to conduct broking and dealing of type 1 and type 2 financial instruments and agency or intermediary service for entry into investment advisory or discretionary investment contracts. This report is intended for distribution only to professional investors (Tokutei Toushika) and is not intended for, and should not be relied upon by, ordinary customers (Ippan Toushika).

The ratings stated on the document are not provided by rating agencies registered with the Financial Services Agency of Japan (JFSA) but by group companies of JFSA-registered rating agencies. These group companies may include Moody's Investors Services Inc., Standard & Poor's Rating Services and/or Fitch Ratings. Any decisions to invest in securities or transactions should be made after reviewing policies and methodologies used for assigning credit ratings and assumptions, significance and limitations of the credit ratings stated on the respective rating agencies' websites.

About Wells Fargo Securities

Wells Fargo Securities is the trade name for the capital markets and investment banking services of Wells Fargo & Company and its subsidiaries, including but not limited to Wells Fargo Securities, LLC, a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of NYSE, FINRA, NFA and SIPC, Wells Fargo Institutional Securities, LLC, a member of FINRA and SIPC, Wells Fargo Prime Services, LLC, a member of FINRA, NFA and SIPC, Wells Fargo Securities Canada, Ltd., a member of IIROC and CIPF, Wells Fargo Bank, N.A. and Wells Fargo Securities International Limited, authorized and regulated by the Financial Conduct Authority.

This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments named or described in this report. Interested parties are advised to contact the entity with which they deal, or the entity that provided this report to them, if they desire further information. The information in this report has been obtained or derived from sources believed by Wells Fargo Securities, LLC, to be reliable, but Wells Fargo Securities, LLC does not represent that this information is accurate or complete. Any opinions or estimates contained in this report represent the judgment of Wells Fargo Securities, LLC, at this time, and are subject to change without notice. For the purposes of the U.K. Financial Conduct Authority's rules, this report constitutes impartial investment research. Each of Wells Fargo Securities, LLC and Wells Fargo Securities International Limited is a separate legal entity and distinct from affiliated banks. Copyright © 2015 Wells Fargo Securities, LLC.

SECURITIES: NOT FDIC-INSURED/NOT BANK-GUARANTEED/MAY LOSE VALUE